Ancora Advisors’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Ancora Advisors’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-533	Closed	-$2.76K	–	1881
2023 Q3	$2.76K	Hold	533	–	–	﹤0.01%	1460
2023 Q2	$4.55K	Hold	533	–	–	﹤0.01%	1394
2023 Q1	$6.29K	Hold	533	–	–	﹤0.01%	1367
2022 Q4	$8K	Hold	533	–	–	﹤0.01%	1404
2022 Q3	$27K	Sell	533 -525	-50%	-$36.5K	﹤0.01%	1271
2022 Q2	$90K	Buy	1,058 +533	+102%	+$45.6K	﹤0.01%	1008
2022 Q1	$79K	Buy	525 +127	+32%	+$29.3K	﹤0.01%	1102
2021 Q4	$119K	Buy	398 +166	+72%	+$63.7K	﹤0.01%	977
2021 Q3	$90K	Buy	232 +99	+74%	+$42.2K	﹤0.01%	1011
2021 Q2	$56K	Buy	+133	New	+$57.6K	﹤0.01%	1067

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ancora Advisors's FNCH Position: Q4 2023 in Review

Ancora Advisors sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q4 2023, closing a stake of 533 shares — an estimated $2.76K sold.

Ancora Advisors first reported a position in FNCH in Q2 2021 and held it in 10 quarters. The position peaked at $119K in Q4 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q4 2023.

Ancora Advisors reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Ancora Advisors sold 533 Finch Therapeutics Group, Inc. Common Stock shares in Q4 2023, an estimated $2.76K.
Ancora Advisors first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Ancora Advisors's Finch Therapeutics Group, Inc. Common Stock position peaked at $119K in Q4 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q4 2023.

Based on Ancora Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.